Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results

BETHESDA, Md., Oct. 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, November 6, 2008, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its third quarter 2008 financial results. Micromet anticipates releasing its financial results at 7:00 am Eastern Time (1:00 pm Central European Time) on Thursday, November 6, 2008.

To participate in this conference call, dial 800-299-0148 (U.S.) or 617-801-9711 (international), passcode: 70506651. The audio webcast can be accessed at: in the investor relations section of the website.

A replay of the call will be available from 12:00 pm Eastern Time on November 6, 2008 (6:00 pm Central European Time) through Thursday, November 13, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 99269687.

About Micromet, Inc.

Micromet, Inc. ( is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody blinatumomab (MT103/MEDI-538) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody that targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, respectively, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed with the SEC on March 14, 2008, as well as other filings by the company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
4. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
5. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
6. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
7. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
8. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
9. Avicena Group to Present at Noble Financial Conference
10. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr ... company’s fast growing clinical data solutions business. , Jeff Parr has spent the past ... sizes, including Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. ...
(Date:10/13/2015)... the United States , Canada ... of all new cases of kidney cancer.   --> ... and Europe .  PRCC represents about 14% of ... China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma ... have completed enrolment in a global Phase II study of savolitinib ...
(Date:10/12/2015)... , Oct. 12, 2015 This report ... which include cell type, products, applications, end-user markets and ... REPORT HIGHLIGHTS The global cell expansion market generated ... expected to reach revenues of $9.7 billion in 2015 ... growth rate (CAGR) of 17.8% from 2015 to 2020. ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
Breaking Biology News(10 mins):